Walden Biosciences

Walden Biosciences is a biotechnology company founded in 2020, with a focus on transforming the treatment of kidney disease. Their slogan "Transforming the Treatment of Kidney Disease" underlines their mission. The company is dedicated to developing first-in-class, highly-targeted therapies for individuals living with kidney disease, aiming to reverse its progression. They are leveraging their comprehensive knowledge and understanding of novel kidney-specific biological pathways and their team’s track record in drug discovery to achieve success. Walden Biosciences' last investment, a Series B round at 01 October 2023, was led by ATEM Capital. The company's collaborative and entrepreneurial culture drives a dynamic team, emphasizing data-driven decision-making and innovation. Based in the heart of Cambridge, MA, between Harvard, MIT, and Massachusetts General Hospital, the company benefits from a prime location for research and development in the biotechnology and healthcare industries. Overall, Walden Biosciences possesses an innovative approach to tackling kidney disease, with a strong emphasis on cutting-edge research and a promising track record, making them an attractive opportunity for venture capital investments.